CLCS Cell Source, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1569340 · Fiscal year ends 12/31
Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.8%
TTM EPS YoY12.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-2,516.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6,985.4%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-857.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q22023-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $483,404 | $315,811 | $470,768 | $373,668 | $781,916 | $506,950 | $480,875 | $539,877 |
| Operating income | -$998,587 | -$676,811 | -$831,625 | -$1.19M | -$1.14M | -$1.01M | -$995,380 | -$905,465 |
| Net income | -$1.48M | -$331,307 | -$1.42M | -$1.49M | -$1.28M | -$1.05M | -$1.34M | -$1.24M |
| EPS (basic) | -0.04 | — | -0.04 | -0.04 | -0.04 | — | -0.04 | -0.04 |
| EPS (diluted) | -0.04 | — | -0.04 | -0.04 | -0.04 | — | -0.04 | -0.04 |
| Weighted avg. shares (diluted) | 45.04M | — | 42.43M | 41.02M | 40.51M | — | 38.19M | 37.21M |
| Balance sheet | ||||||||
| Cash & equivalents | $1,240 | $74,631 | $22,992 | $90,549 | $23 | $22,203 | $2,582 | $21,993 |
| Total assets | $292,446 | $286,500 | $264,660 | $429,767 | $82,589 | $195,171 | $248,357 | $362,329 |
| Total liabilities | $20.43M | $18.82M | $19.21M | $17.75M | $16.84M | $15.81M | $16.28M | $15.31M |
| Shareholders' equity | -$20.14M | -$18.54M | -$18.94M | -$17.32M | -$16.75M | -$15.61M | -$16.03M | -$14.95M |
| Shares outstanding | 45.04M | 45.04M | 43.25M | 41.94M | 41.02M | 39.83M | 38.50M | 38.16M |
| Cash flow statement | ||||||||
| Operating cash flow | -$600,391 | -$748,326 | -$639,010 | -$1.12M | -$173,852 | -$722,290 | -$279,969 | -$1.04M |
| Financing cash flow | $527,000 | $799,965 | $571,453 | $1.21M | $151,672 | $741,911 | $260,558 | $925,000 |
| Stock-based compensation | $104,475 | -$20,873 | $5,070 | $15,332 | $288,895 | $58,056 | $25,962 | $50,111 |
Free plan shows the latest 8 periods; Pro shows all 50 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.